Conclusions-In this study, we provide evidence that the recessive inheritance of a severe long-QT syndrome type 1 phenotype in the absence of an auditory phenotype may represent a more common pattern of long-QT syndrome inheritance than previously anticipated and that these cases should be treated as a higher-risk long-QT syndrome subset similar to their Jervell and Lange-Nielsen syndrome counterparts. Furthermore, mutation type may serve as a genetic determinant of deafness, but not cardiac expressivity, in individuals harboring ≥1 KCNQ1 mutation on each allele. (Circ Cardiovasc Genet. 2013;6:193-200.) The online-only Data Supplement is available at http://circgenetics.ahajournals.org/lookup/suppl/
C ongenital long-QT syndrome (LQTS) is characterized by a prolonged heart rate-corrected QT interval (QTc) on ECG and an increased risk of syncope and sudden death secondary to polymorphic ventricular arrhythmias. 1 Loss-offunction mutations in the KCNQ1-encoded Kv7.1 potassium channel, which conducts the slowly activating delayed rectifier outward K + current in the heart 2 and inner ear, 3 cause type 1 LQTS (LQT1), 4 the most common genetic subtype of LQTS. 5, 6 Classically, LQTS assumes 2 clinically recognized forms: autosomal-dominant Romano-Ward syndrome, which affects between 1 in 2000 and 1 in 5000 individuals and presents with only a cardiac phenotype, 7 and the extremely rare (<1 per 4 million), autosomal-recessive (AR) Jervell and Lange-Nielsen syndrome (JLNS), which presents with a malignant cardiac phenotype and congenital bilateral sensorineural deafness. 8, 9 
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Although individuals homozygous or compound-heterozygous for KCNQ1 disease-causative mutations typically present with JLNS, during the past decade, isolated reports of homozygous or compound-heterozygous individuals presenting with only cardiac manifestations in the absence of deafness (so-called AR Romano-Ward syndrome/LQT1 or AR LQT1) have surfaced in the literature. [10] [11] [12] [13] [14] It has been postulated that hearing preservation in these KCNQ1 homozygotes/compound heterozygotes stems from the presence of milder mutations that fail to completely abolish Kv7.1 function, resulting in sufficient residual K + current to maintain normal K + cycling in the inner ear but not the normal electric activity of the heart. 10, 11, 15 However, aside from a single individual with intact hearing who was found to harbor a homozygous splice-site mutation (c.387-5 T>A) in exon 2 of KCNQ1 that results in incomplete exon skipping, 14 few insights into the overall prevalence of KCNQ1 homozygosity/compound heterozygosity without sensorineural deafness and the genetic determinants underlying hearing preservation in these individuals exist.
Thus, we performed a retrospective analysis of LQTS patients evaluated at the Mayo Clinic to determine the overall Background-Homozygous or compound heterozygous mutations in KCNQ1 cause Jervell and Lange-Nielsen syndrome, a rare, autosomal-recessive form of long-QT syndrome characterized by deafness, marked QT prolongation, and a high risk of sudden death. However, it is not understood why some individuals with mutations on both KCNQ1 alleles present without deafness. In this study, we sought to determine the prevalence and genetic determinants of this phenomenon in a large referral population of patients with long-QT syndrome.
Methods and Results-A retrospective analysis of all patients with long-QT syndrome evaluated from July 1998 to April 2012 was used to identify those with ≥1 KCNQ1 mutation. Of the 249 KCNQ1-positive patients identified, 15 (6.0%) harbored a rare putative pathogenic mutation on both KCNQ1 alleles. Surprisingly, 11 of these patients (73%) presented without the sensorineural deafness associated with Jervell and Lange-Nielsen syndrome. The degree of QT-interval prolongation and the number of breakthrough cardiac events were similar between patients with and without deafness. Interestingly, truncating mutations were more prevalent in patients with Jervell and Lange-Nielsen syndrome (79%) than in nondeaf patients (36%; P<0.001) derived from this study and those in the literature.
prevalence, degree of cardiac expressivity, and spectrum of auditory phenotypes associated with individuals harboring a mutation on both KCNQ1 alleles and to determine whether mutation type or topological location of mutations in the Kv7.1 channel represents a genetic determinant of sensorineural deafness in KCNQ1 homozygotes/compound heterozygotes.
Methods

Study Population
In this Mayo Clinic Institutional Review Board-approved study, a retrospective review of all patients seen in the LQTS clinic from July 1998 to April 2012 was used to identify all patients with ≥1 LQT1associated mutations in the KCNQ1-encoded Kv7.1 potassium channel. Of the 249 KCNQ1-positive patients (average age at evaluation, 21±16; average QTc, 466±42 milliseconds), those patients harboring (1) a single KCNQ1 mutation, (2) mutation(s) observed in >0.5% of ostensibly healthy individuals in either the National Heart, Lung, and Blood Institute Exome Sequencing Project or 1000 genomes public data sets, (3) multiple KCNQ1 mutations on the same allele, or (4) additional mutations in other channelopathic genes were excluded from the analysis. Furthermore, individuals with acquired cardiac diseases, with electrolyte abnormalities, or receiving QT prolonging medications were also excluded.
The following parameters were obtained from the electronic medical records of each family member: age, sex, proband status, family history of sudden death, incidence of torsades de pointes, documented ventricular fibrillation, syncopal episodes, β-blocker status, implantable cardioverter-defibrillator status, pertinent surgical interventions such as left cardiac sympathetic denervation and right cardiac sympathetic denervation, and type of KCNQ1 mutation(s). The researcher (J.G.) who obtained the clinical parameters and analyzed ECGs was blinded initially to the mutation type and auditory phenotype of each patient.
ECG Analysis
Twelve-lead ECGs were analyzed manually, and the QT duration (lead II or V 5 ) was corrected for heart rate with the Bazett formula (QTc=QT/√RR). The QTc value for each individual represents the mean value of 5 consecutive beats and is reported in milliseconds.
Genetic Analysis
The identification of LQT1-associated mutations in KCNQ1 was accomplished either with commercial genetic testing or through the use of laboratory-based genetic testing using mutation detection protocols described previously. 16 
Genotype-Phenotype Correlation Analysis
Given the rare nature of biallelic inheritance of 2 KCNQ1 mutations, for the purposes of identifying potential genotype-phenotype correlations, the results of the present study were combined with several large JLNS cases series 17, 18 and AR LQT1 case reports 10, 11, 13, 14 in the literature in which full genotypic information was available. The literaturederived unrelated JLNS and AR LQT1 cases used in this analysis are detailed in Table I in the online-only Data Supplement.
Statistical Methods
Univariate analysis was used to compare groups identified on the basis of clinical (eg, sensorineural deafness) or molecular (eg, truncating mutations) characteristics. All continuous variables are presented as mean±SD. The Fisher exact test was used to compare categorical variables, and the Wilcoxon rank-sum/Mann-Whitney U test was used to compare continuous variables. For both tests, a value of P≤0.05 was considered statistically significant. The authors had full access to and take full responsibility for the integrity of the data. Both authors have read and agree to the article as written.
Results
Prevalence and Clinical Evaluation of KCNQ1 Homozygotes/Compound Heterozygotes Referred to the Mayo Clinic
Of the 249 KCNQ1-positive patients evaluated at the Mayo Clinic LQTS clinic between July 1998 and April 2012, 15 patients (6.0%) harbored rare, potentially pathogenic mutations on both KCNQ1 alleles. Surprisingly, 11 of these double-KCNQ1-positive individuals (73%) presented without the sensorineural deafness/hearing loss typically associated with JLNS and thus are best defined as recessive LQT1 (AR LQT1) cases. Pertinent clinical information on cardiac expressivity and auditory phenotype of each KCNQ1 homozygote/compound heterozygote is summarized in Table 1 . Pedigree structures and genotypic information of AR LQT1 and JLNS families are detailed in Figures 1 and 2 , respectively. Brief clinical/family histories for the 14 patients not previously described in the literature are provided in the online-only Data Supplement.
Clinical Characteristics of Patients Homozygous or Compound Heterozygous for Mutations in the KCNQ1-Encoded Kv7.1 Potassium Channel
The clinical characteristics of the 15 individuals homozygous or compound heterozygous for mutations in KCNQ1 are summarized in Table 2 . Interestingly, those patients defined as AR LQT1 (ie, intact hearing) were significantly more likely to have a positive family of sudden unexplained death or LQTS (91%) compared with JLNS cases (25%; P≤0.05). Indicators of the severity of the cardiac phenotype such as previously suffering a cardiac event (defined as syncope, documented ventricular fibrillation/ventricular tachycardia, or cardiac arrest) and the degree of QTc prolongation were statistically similar between JLNS and AR LQT1 patients (Table 2 ). Furthermore, AR LQT1 patients trended toward a higher likelihood of suffering from at least 1 syncopal episode (100%) compared with their JLNS counterparts (50%; P=0.06; Table 2 ). However, this observation may reflect the small sample size.
Clinical Characteristics of the Parents of KCNQ1 Homozygotes/Compound Heterozygotes
Complete clinical demographics were available on 21 of 28 AR LQT1/JLNS parents (Table 3 ). Unfortunately, clinical information was not available on 7 AR LQT1/JLNS parents who either died of noncardiac causes before their child's LQTS diagnosis (n=3) or declined further participation in this study (n=4). Nevertheless, only 25% of the parents with available clinical information, who by definition are obligate positive for 1 KCNQ1 mutation, displayed phenotypic manifestations suggestive of LQTS (eg, symptoms or a resting QTc ≥470 milliseconds in male or ≥480 milliseconds in female patients; Figure 3 ). There was no statistical difference in the percentage of parents of JLNS compound heterozygotes or parents of nondeaf compound heterozygotes who displayed objective phenotypic manifestations of LQTS ( Figure 3 ). Furthermore, no statistically significant differences in the average QTc, percentage of symptomatic parents, or percentage of parents requiring clinical management of their LQT1 genetic substrate were observed between parents of JLNS and nondeaf compound heterozygotes (Table 3 ).
Potential Genetic Determinants of Auditory/ Deafness Phenotype in KCNQ1 Homozygosity/ Compound Heterozygosity
To strengthen the identification of potential AR LQT1/JLNS genotype-phenotype correlations, the patients described in the present study were combined and analyzed with JLNS and AR LQT1 patients derived from case series 17, 18 or case reports 10, 11, 13, 14 in the literature. A breakdown of KCNQ1 mutations in this combined analysis by mutation type is summarized in Figure 4A . To allow further statistical comparison, mutations were classified subsequently as either nontruncating (eg, missense or in-frame deletion) or truncating (eg, nonsense, frame-shift, or splice-site) mutations to reflect shared effects on protein structure. Interestingly, JLNS patients were significantly more likely to harbor truncating mutations (79%) than AR LQT1 patients (36%; P<0.001; Figure 4B ). No statistical difference in the localization of AR LQT1-or JLNS-causative mutations to specific regions of the Kv7.1 channel topology was observed ( Figure 4C ).
Discussion
Prevalence and Inheritance Patterns of KCNQ1 Homozygosity/Compound Heterozygosity
The observation that marked variable penetrance and expressivity are hallmarks of LQTS has led some to hypothesize that widespread genetic testing in the general population may result in the identification of a surprisingly high number of low-frequency, reduced-penetrance mutations that manifest clinically only when other genetic (eg, presence of a similar reducedpenetrance mutation on the opposite allele) or environmental factors (eg, QT-prolonging drugs) are present. 10, 21, 22 Indeed, the release of large-scale exome sequencing data from the National Heart, Lung, and Blood Institute Exome Sequencing Project revealed that 1 in 31 individuals (3%) harbor a rare genetic variant in 1 of the 13 established LQTSsusceptibility genes. 23 Although the vast majority of established LQTS-associated mutations (94.8%), including all but the KCNQ1-R518X mutation described in the present study, are absent from the National Heart, Lung, and Blood Institute Exome Sequencing Project, 9 rare missense or nonsense variants, previously associated with LQT1, were identified in KCNQ1 alone. 23 This would place the prevalence of a heterozygous LQT1 genotype between 1 in 600 and 1 in 1080 in the general population, far greater than the estimated LQT1 disease prevalence of ≈1 in 7500 (1 in 2500 estimate for LQTS, of which approximately one third is attributed to LQT1). 24 Although many of the rare LQTS-associated variants identified in Exome Sequencing Project individuals are likely to be innocuous bystanders that slipped through the cracks, the discordance between the prevalence of functional/cosegregating KCNQ1 variants and overall LQTS disease prevalence may suggest that a subset of KCNQ1 variants, with defined pathogenic influence, are at best infrequent causes of monogenic disease in isolation. Furthermore, this observation suggests that the number of individuals who are compound heterozygous (or less likely homozygous) for rare potentially pathogenic KCNQ1 mutations exceeds the estimated prevalence of 1 in 4 million to 1 in 25 million derived from overall LQTS disease prevalence.
Given the severe clinical course experienced by 12 of 14 unrelated individuals (86%) who have a rare variant on each KCNQ1 allele (eg, QTc >500 milliseconds with documented cardiac events) and the concealed phenotype observed in the majority of their heterozygous parents/family members assessed, it is not surprising that the pedigree structures of at least 11 of the 14 families in this study (79%) display a probable AR 
Spectrum of Auditory/Deafness Phenotype and Degree of Cardiac Expressivity in KCNQ1 Homozygotes/Compound Heterozygotes
More than a decade ago, Priori et al 10 provided the first clinical and molecular evidence that homozygous or compoundheterozygous mutations in KCNQ1 do not invariably lead to . This 3-generation pedigree is notable for the index case with severe QT prolongation who suffered from breakthrough syncopal episodes before undergoing a left cardiac sympathetic denervation (LCSD) (III.1). B, Family AR LQT1b. This 3-generation pedigree is notable for the index case with severe QT prolongation and a history of breakthrough cardiac events (III.1). C, Family AR LQT1c. This 3-generation pedigree is notable for the index case with severe QT prolongation and a history of breakthrough cardiac events, including an out-of-hospital cardiac arrest (III.1), and her brother who also has severe QT prolongation and has suffered multiple breakthrough cardiac events, including an implantable cardioverter-defibrillator storm (III.4). D, Family AR LQT1d. This 2-generation pedigree is notable only for the index case who displays extreme QT prolongation and suffered multiple breakthrough cardiac events before succumbing to his malignant LQTS phenotype at the age of 3 years (II.1). E, Family AR LQT1e. This 4-generation pedigree is notable for the index case with QT prolongation who suffered numerous exertional syncopal episodes during childhood (III.4). F, Family AR LQT1f. This 3-generation pedigree is notable for the index case who features a prolonged QT interval but has remained asymptomatic for the last 25 years (III.9) and the sudden unexplained deaths of her siblings at the age of 13 and 3 years, respectively (III.7 and III.10). G, Family AR LQT1g. This 2-generation pedigree is notable for the index case with QT prolongation (III.1) and the swimming-triggered sudden unexplained death of the 13-year-old sister of the index case (III.3). H, Family AR LQT1h. This 2-generation pedigree is notable for the index case who has severe QT prolongation and suffered several breakthrough implantable cardioverter-defibrillator shocks before undergoing an LCSD (III.2). I, Family AR LQT1i. This 2-generation pedigree is notable for the index case who has QT prolongation and suffered several breakthrough cardiac events, including an out-of-hospital cardiac arrest (III.4). J, Family AR LQT1j. This 2-generation pedigree is notable for the symptomatic index case that has QT prolongation (III.2).
JLNS. Although several additional case reports confirmed that AR LQT1 is not an isolated phenomenon [11] [12] [13] [14] and previous studies have assessed the prevalence and phenotypic severity of a compound/digenic hetorozygosity involving the 3 major LQTS-susceptibility genes, 5, 25, 26 the prevalence of sensorineural hearing loss and degree of cardiac expressivity in individuals with mutations on both KCNQ1 alleles remains undefined. Surprisingly, the present study suggests that the majority of unrelated KCNQ1 homozygotes/compound heterozygotes with a probable AR pattern of inheritance (7 of 11, 64%) present without sensorineural hearing loss. To the best of our knowledge, even when cases with an uncertain pattern of inheritance are excluded, this study still more than doubles (from 4 to 11) the number of individuals with intact hearing despite homozygous or compound-heterozygous mutations in KCNQ1 that have been described in the literature. Thus, this report provides further evidence that the 2 traditional patterns of LQTS inheritance, autosomal-dominant Romano-Ward syndrome with cardiac phenotype only and AR JLNS with cardiac phenotype and sensorineural deafness, inadequately describe the full spectrum of inheritance patterns observed in LQTS patients.
In addition to providing evidence that the existing patterns of LQTS inheritance should be expanded to include instances when the LQTS cardiac phenotype is inherited in a recessive manner without a discernible auditory phenotype, culminating in what is best described as recessive Romano-Ward syndrome/AR LQT1, this study provides additional evi dence that JLNS and recessive Romano-Ward syndrome/AR LQT1 homozygotes/compound heterozygotes represent equally high-risk LQTS subsets that are both prone to suffering breakthrough cardiac events. Given that JLNS and AR LQT1 individuals share similarly severe clinical courses, the early initiation of surgical options such as prophylactic left cardiac sympathetic dener vation or implantable cardioverter-defibrillator implantation for secondary prevention, in addition to β-blockers merits serious consideration as a means of further reducing the risk of sudden death in these higher-risk LQTS populations. 
Genetic Determinants of Sensorineural Hearing Loss in KCNQ1 Homozygosity/Compound Heterozygosity
Although most LQT1-causative mutations are nontruncating missense mutations capable of exerting a dominant-negative effect on channel function, 5 most JLNS1-causative mutations are truncating nonsense or frame-shift mutations that likely abolish the ability of mutant α subunits to posttranslationally coassemble, thereby resulting in a nonfunctioning channel when expressed in isolation and haploinsufficiency when coexpressed with a wild-type subunit. 21, 27 Not surprisingly, 79% of JLNS mutations identified in the cases analyzed for this study were truncating, consistent with previous observations. 17, 21, 28 However, this observation did not extend to the 14 newly and previously described unrelated AR LQT1 cases in which only 36% of individuals harbored truncating mutations that were expected to result in KCNQ1 haploinsuffiency. Thus, this study provides preliminary evidence that KCNQ1 mutation type represents a major differentiating factor between JLNS and AR LQT1 and thus may play a role in determining the presence or absence of an auditory phenotype. Furthermore, this study suggests that the residual Kv7.1 function needed to maintain the normal secretion of K + into the endolymphatic compartment partially responsible for generating the endocochlear potential in the inner ear must be fairly low. Interestingly, through the study of a patient homozygous for the incomplete exon skipping c.387-5 T>A splice-site mutation, Bhuiyan and colleagues were able to demonstrate that the degree of residual Kv7.1 function required for hearing preservation is roughly 10%. 14 Although the present study cannot improve on the numeric Kv7.1 threshold required for hearing preservation, it is clear from this study and others that the complete cessation of Kv7.1-mediated K + secretion in the inner ear linked to the biallelic inheritance of 2 truncating/haploinsufficient mutations is the primary mechanism that disrupts cochlear fluid homeostasis, resulting in the collapse of endolymphatic compartment and sensorineural deafness in JLNS patients and murine JLNS models. 29, 30 Thus, current evidence places the threshold for hearing preservation in KCNQ1 homozygosity/compound heterozygosity at >0% but ≤10% residual Kv7.1 function. Functional investigation of unique or unexpected AR LQT1 and JLNS mutation combinations, perhaps by using patient-specific induced pluripotent stem cell models that more accurately recapitulate a endocochlear/cardiac environment, may shed more light on this interesting phenomenon and help to precisely define the degree of residual Kv7.1 function required for hearing preservation in KCNQ1 homozygosity/compound heterozygosity.
Limitations
As a result of the rarity of KCNQ1 homozygosity/compound heterozygosity and the single-center nature of this study, only 15 patients from 14 unrelated families were enrolled in this study. However, to the best of our knowledge, this study represents the only attempt in the literature to assess the overall prevalence and phenotypic spectrum of all KCNQ1 compound heterozygotes, not just JLNS, evaluated at a single referral center. Although every attempt was made to gather clinical information and genetic material on as many family members as possible, because of death or refusal of further participation, clinical information and DNA were not available on all parents and extended family members. As a result, we were unable to fully assess the inheritance patterns, clinical characteristics, and potential genetic determinants of cardiac/auditory phenotype in a few of the pedigrees included in this study. Additionally, emerging evidence in the literature suggests that KCNQ1 homozygosity/compound heterozygosity resulting in JLNS may also be accompanied by additional hematologic and gastrointestinal manifestations. 31, 32 Unfortunately, clinical data such as serum gastrin levels pertinent to these additional phenotypic manifestations were not available for the patients enrolled in this study. Thus, it remains to be seen whether AR LQT1 patients are susceptible to hematologic and gastrointestinal pathologies similar to those described previously for JLNS.
Given the referral nature of our LQTS clinic, it is also possible that the observed 6% frequency of biallelic KCNQ1 mutations is an overestimate of the actual frequency/burden of multiple-hit KCNQ1-mediated disease. Patients with LQT1 and recurrent symptoms despite β-blocker therapy have been referred increasingly over the years for left cardiac sympathetic denervation therapy and thus may be overrepresented in this cohort, which could inflate the apparent frequency of compound-mutation LQT1.
Lastly, the vast majority of KCNQ1 mutations identified in this study have not been characterized functionally. Without an electrophysiological phenotype, it is difficult to assess the mechanism (eg, dominant-negative versus haploinsufficiency) and the relative strength of the electrophysiological phenotype of each mutation. It is certainly possible that both mutation mechanism and electrophysiological phenotype could shed even more light on the potential genetic mechanisms and determinants underlying the phenotypic presentation of KCNQ1 homozygotes/compound heterozygotes identified in this study. However, even without an electrophysiological phenotype on each of the 22 mutations identified, we were able to glean new observations in regard to the genetic determinants that may partially define the severity of the cardiac/ auditory phenotype in KCNQ1 homozygosity/compound heterozygosity.
Conclusions
By increasing the number of recessive LQT1 cases reported in the literature, this study provides compelling evidence that the recessive inheritance of a severe LQTS cardiac phenotype in the absence of an auditory phenotype may represent a more common pattern of LQTS inheritance than previously anticipated. Furthermore, given the severe clinical course and high rate of breakthrough cardiac events observed in recessive LQTS cases, this study suggests that these individuals should be treated as a higher-risk LQTS subgroup similar to their JLNS counterparts. In other words, normal hearing in a patient with multiple mutations in LQT1 should not result in a better cardiac prognosis than for a deaf patient with LQT1 (JLNS). Lastly, this study provides preliminary evidence that KCNQ1 mutation type functions as a genetic determinant of sensorineural deafness, but not cardiac expressivity, in KCNQ1 homozygosity/compound heterozygosity. 
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